Peptide aptamers: recent developments for cancer therapy

Bibliography

• FELSHER DW: Reversibility of oncogene-induced cancer. Curr. Opin. Genet. Dev. (2004) 14(1):37–42.
   PubMed Web of Science ®Google Scholar
• ••Review of conditional oncogene expressionin mouse models and consequences for the transformed phenotype.
   Google Scholar
• GIURIATO S, RABIN K, FAN AC, SHACHAF CM, FELSHER DW: Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin. Cancer Biol. (2004) 14(1):3–11.
   PubMed Web of Science ®Google Scholar
• FELSHER DW, BISHOP JM: Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Nail. Acad. Sci. USA (1999) 96(7):3940–3944.
   PubMed Web of Science ®Google Scholar
• CHIN L, TAM A. POMERANTZ J et al.: Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 400(6743):468–472.
   Google Scholar
• FISHER GH, WELLEN SL, KLIMSTRA D et al.: Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. (2001) 15(24):3249–3262.
   PubMed Web of Science ®Google Scholar
• GUNTHER EJ, MOODY SE, BELKA GK et al.: Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. (2003) 17(4):488–501.
   PubMed Web of Science ®Google Scholar
• HUETTNER CS, ZHANG P, VAN ETTEN RA, TENEN DG: Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. (2000) 24(1):57–60.
   PubMed Web of Science ®Google Scholar
• EWALD D, LI M, EFRAT S et al.: Time-sensitive reversal of hyperplasia in transgenic mice expressing 5V40 T antigen. Science (1996) 273(5280):1384–1386.
   PubMed Web of Science ®Google Scholar
• JAIN M, ARVANITIS C, CHU K et al: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 297(5578):102–104.
   PubMed Web of Science ®Google Scholar
• ••Influence of reversible myc gene expressionon cell differentiation and tumourigenisis in osteoblasts.
   Google Scholar
• WANG R, FERRELL LD, FAOUZI S, MAHER JJ, BISHOP JM: Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol (2001) 153(5):1023–1034.
   PubMed Web of Science ®Google Scholar
• XIE W, CHOW LT, PATERSON AJ, CHIN E, KUDLOW JE: Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice. Oncogene (1999) 18(24):3593–3607.
   PubMed Web of Science ®Google Scholar
• MOODY SE, SARKISIAN CJ, HAHN KT et al.: Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 2(61:451–461.
   PubMedGoogle Scholar
• COLAS P, COHEN B, JESSEN T et al: Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature (1996) 380(6574):548–550.
   PubMed Web of Science ®Google Scholar
• ••Intracellular inhibition of cdk activity by apeptide aptamer.
   Google Scholar
• COLAS P: Combinatorial protein reagents to manipulate protein function. Curr. Opin. Chem. Biol. (2000) 4(1):54–59.
   PubMed Web of Science ®Google Scholar
• GEYER CR, BRENT R: Selection of genetic agents from random peptide aptamer expression libraries. Methods Enqmol. (2000) 328:171–208.
   PubMed Web of Science ®Google Scholar
• LADNER RC: Constrained peptides as binding entities. Trends Biotech. (1995) 13(10):426–430.
   PubMed Web of Science ®Google Scholar
• HOLMGREN A, SODERBERG BO, EKLUND H, BRANDEN CI: Three-dimensional structure of Escherichia coli thioredoxin-52 to 2.8 A resolution. Proc. Natl Acad. Sci. USA (1975) 72(0:2305–2309.
   Google Scholar
• MYSZKA DG, CHAIKEN IM: Design and characterization of an intramolecular antiparallel coiled coil peptide. Biochemistry (1994) 33(9):2363–2372.
   PubMed Web of Science ®Google Scholar
• LUPAS A: Coiled coils: new structures and new functions. Trends Biochem. Sci. (1996) 21(10):375–382.
   PubMed Web of Science ®Google Scholar
• MICELI R, MYSZKA D, MAO J, SATHE G, CHAIKEN I: The coiled coil stem loop miniprotein as a presentation scaffold. Drug Des. Discov. (1996) 13(3-4):95–105.
   PubMedGoogle Scholar
• LI C, PLUGARIU CG, BAJGIER J et al.: Coiled coil miniprotein randomization on phage leads to charge pattern mimicry of the receptor recognition determinant of interleukin 5.1 Md. Recognit. (2002) 15(1):33–43.
   Google Scholar
• PACK P, MULLER K, ZAHN R, PLUCKTHUN A: Tetravalent miniantibodies with high avidity assembling in Escherichia coli. j MoL Biol. (1995) 246(1):28–34.
   PubMed Web of Science ®Google Scholar
• TANG A, WANG C, STEWART R, KOPECEK J: Self-assembled peptides exposing epitopes recognizable by human lymphoma cells. Bioconjug Chem. (2000) 11(3):363–371.
   PubMed Web of Science ®Google Scholar
• TERSKIKH AV, LE DOUSSAL JM, CRAMERI R et al.: `Peptabody': a new type of high avidity binding protein. Proc. Natl Acad. Sci. USA (1997) 94(5):1663–1668.
   PubMed Web of Science ®Google Scholar
• BODENMULLER H, SCHILLING E, ZACHMANN B, SCHALLER HC: The neuropeptide head activator loses its biological activity by dimerization. EMBO J. (1986) 5(8):1825–1829.
   PubMed Web of Science ®Google Scholar
• GURURAJA TL, NARASIMHAMURTHY S, PAYAN DG, ANDERSON DC: A novel artificial loop scaffold for the noncovalent constraint of peptides. Chem. Biol. (2000) 7(7):515–527.
   PubMed Web of Science ®Google Scholar
• MARKS KM, ROSINOV M, NOLAN GP: In vivo targeting of organic calcium sensors via genetically selected peptides. Chem. Biol. (2004) 11(3):347–356.
   PubMed Web of Science ®Google Scholar
• NORMAN TC, SMITH DL, SORGER PK et al.: Genetic selection of peptide inhibitors of biological pathways. Science (1999) 285(5427):591–595.
   PubMed Web of Science ®Google Scholar
• SERPERSU EH, SHORTLE D, MILDVAN AS: Kinetic and magnetic resonance studies of active-site mutants of staphylococcal nuclease: factors contributing to catalysis. Biochemistry (1987) 26(5):1289–1300.
   PubMed Web of Science ®Google Scholar
• ABEDI MR, CAPONIGRO G, KAMB A: Green fluorescent protein as a scaffold for intracellular presentation of peptides. Nucleic Acids Res. (1998) 26(2):623–630.
   PubMed Web of Science ®Google Scholar
• KLEVENZ B, BUTZ K, HOPPE-SEYLER F: Peptide aptamers: exchange of the thioredoxin-A scaffold by alternative platform proteins and its influence on target protein binding. Cell Mol. Lift Sci. (2002) 59(11):1993–1998.
   PubMed Web of Science ®Google Scholar
• PEELLE B, GURURAJA TL, PAYAN DG, ANDERSON DC: Characterization and use of green fluorescent proteins from Renilla mulleri and Ptilosarcus guernyi for the human cell display of functional peptides. J. Protein Chem. (2001) 20(6):507–519.
   PubMedGoogle Scholar
• LEHTIO J, TEERI TT, NYGREN PA: Alpha-amylase inhibitors selected from a combinatorial library of a cellulose binding domain scaffold. Proteins (2000) 41(3):316–322.
   PubMed Web of Science ®Google Scholar
• SMITH GP, PATEL SU, WINDASS JD et al.: Small binding proteins selected from a combinatorial repertoire of knottins displayed on phage. j MoL Biol. (1998) 277(2):317–332.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI M, NOKIHARA K, MIT-IARA H: Construction of a protein-detection system using a loop peptide library with a fluorescence label. Chem. Biol. (2003) 10(1):53–60.
   PubMed Web of Science ®Google Scholar
• MCCONNELL SJ, HOESS RH: Tendamistat as a scaffold for conformationally constrained phage peptide libraries. J. MoL Biol. (1995) 250(4):460–470.
   PubMed Web of Science ®Google Scholar
• KURTZ SE, ESPOSITO K, TANG W, MENZEL R: Inhibition of an activated Ras protein with genetically selected peptide aptamers. BiotechnoL Bioeng. (2003) 82(1):38–46.
   PubMed Web of Science ®Google Scholar
• LADNER RC, SATO AK, GORZELANY J, DE SOUZA M: Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov. Today (2004) 9(12):525–529.
   PubMed Web of Science ®Google Scholar
• MORI T: Cancer-specific ligands identifiedfrom screening of peptide-display libraries. Curr. Pharm. Des. (2004) 10(19):2335–2343.
   PubMed Web of Science ®Google Scholar
• MANCINI N, CARLETTI S, PEROTTI M et al.: Phage display for the production of human monoclonal antibodies against human pathogens. New MicrobioL (2004) 27(4):315–328.
   PubMedGoogle Scholar
• SIDHU SS, FAIRBROTHER WJ, DESHAYES K: Exploring protein-protein interactions with phage display. Chembiochem. (2003) 4(1):14–25.
   PubMed Web of Science ®Google Scholar
• LU Z, MURRAY KS, VAN CLEAVE V et al.: Expression of thioredoxin random peptide libraries on the Ewherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. Biotechnology (NV (1995) 13(4):366–372.
   Google Scholar
• WESTERLUND-WIKSTROM B: Peptide display on bacterial flagella: principles and applications. Int J. Med. MicrobioL (2000) 290(3):223–230.
   PubMed Web of Science ®Google Scholar
• COHEN BA, COLAS P, BRENT R: An artificial cell-cycle inhibitor isolated from a combinatorial library. Proc. Nail. Acad. Sci. USA (1998) 95(24):14272–14277.
   PubMed Web of Science ®Google Scholar
• •Description of the peptide aptamer selection procedures.
   Google Scholar
• GYURIS J, GOLEMIS E, CHERTKOV H, BRENT R: Cdil, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell (1993) 75(4):791–803.
   PubMed Web of Science ®Google Scholar
• FIELDS S, SONG O: A novel genetic system to detect protein-protein interactions. Nature (1989) 340(6230):245–246.
   PubMed Web of Science ®Google Scholar
• BUTZ K, DENK C, FITSCHER B et aL: Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene (2001) 20(45):6579–6586.
   PubMed Web of Science ®Google Scholar
• •Use of peptide aptamers as anti-infectives.
   Google Scholar
• BRODER YC, KATZ S, ARONHEIM A: The ras recruitment system, a novel approach to the study of protein-protein interactions. Cuff. Biol. (1998) 8(20):1121–1124.
   PubMed Web of Science ®Google Scholar
• GALLAGHER WM, CAIRNEY M, SCHOTT B, RONINSON IB, BROWN R: Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene (1997) 14(2):185–193.
   PubMed Web of Science ®Google Scholar
• TAVERNIER J, EYCKERMAN S, LEMMENS I et aL: MAPPIT: a cytokine receptor-based two-hybrid method in mammalian cells. Clin. Exp. Allergy (2002) 32(10):1397–1404.
   PubMed Web of Science ®Google Scholar
• PEELLE B, LORENS J, LI W et aL: Intracellular protein scaffold-mediated display of random peptide libraries for phenotypic screens in mammalian cells. Chem. Biol. (2001) 8(5):521–534.
   PubMed Web of Science ®Google Scholar
• XU X, LEO C, JANG Yet aL: Dominant effector genetics in mammalian cells. Nat. Genet. (2001) 27(1):23–29.
   PubMed Web of Science ®Google Scholar
• •Phenotypic selection of retrovirally encoded peptides from random libraries capable of pathway inhibition.
   Google Scholar
• GEYER CR, COLMAN-LERNER A. BRENT R: `Mutagenesis' by peptide aptamers identifies genetic network members and pathway connections. Proc. NatL Acad. Sci. USA (1999) 96(15):8567–8572.
   PubMed Web of Science ®Google Scholar
• CAPONIGRO G, ABEDI MR, HURLBURT AP et al.: Transdominant genetic analysis of a growth control pathway. Proc. NatL Acad. Sci. USA (1998) 95(13):7508–7513.
   PubMed Web of Science ®Google Scholar
• DEROSSI D, JOLIOT AH, CHASSAING G, PROCHIANTZ A: The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. (1994) 269(14):10444–10450.
   PubMed Web of Science ®Google Scholar
• JOLIOT A, PERNELLE C, DEAGOSTINI-BAZIN H, PROCHIANTZ A: Antennapedia homeobox peptide regulates neural morphogenesis. Proc. NatL Acad. Sci. USA (1991) 88(5):1864–1868.
   PubMed Web of Science ®Google Scholar
• EGUCHI A, AKUTA T, OKUYAMA H et al.: Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. J. Biol. Chem. (2001) 276(28):26204–26210.
   PubMed Web of Science ®Google Scholar
• LEWIN M, CARLESSO N, TUNG CH et al.: Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. BiotechnoL (2000) 18(4):410–414.
   PubMed Web of Science ®Google Scholar
• SCHWARZE SR, HO A, VOCERO-AKBANI A, DOWDY SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science (1999) 285(5433):1569–1572.
   PubMed Web of Science ®Google Scholar
• •Delivery of proteins and peptides via PTD fusion contructs in vivo.
   Google Scholar
• TORCHILIN VP, RAMMOHAN R, WEISSIG V LEVCHENKO TS: TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. NatL Acad. Sci. USA (2001) 98(15):8786–8791.
   PubMed Web of Science ®Google Scholar
• MAI JC, SHEN H, WATKINS SC, CHENG T, ROBBINS PD: Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J. Biol. Chem. (2002) 277(33):30208–30218.
   PubMed Web of Science ®Google Scholar
• SHEN H, MAI JC, QIU L et ell.: Evaluation of peptide-mediated transduction in human CD34+ cells. Hum. Gene Ther. (2004) 15(4):415–419.
   Google Scholar
• WENDER PA, MITCHELL DJ, PATTABIRAMAN K et al.: The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. NatL Acad. Sci. USA (2000) 97(24):13003–13008.
   PubMed Web of Science ®Google Scholar
• TYAGI M, RUSNATI M, PRESTA M, GIACCA M: Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. (2001) 276(5):3254–3261.
   PubMed Web of Science ®Google Scholar
• ZIEGLER A, BLATTER XL, SEELIG A, SEELIG J: Protein transduction domains of HIV-1 and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic analysis. Biochemistry (2003) 42(30):9185–9194.
   Google Scholar
• ZIEGLER A, SEELIG J: Interaction of the protein transduction domain of HIV-1 TAT with heparan sulfate: binding mechanism and thermodynamic parameters. Biophys. (2004) 86(1 Pt 1):254–263.
   Google Scholar
• CARON NJ, QUENNEVILLE SP, TREMBLAY JP: Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins. Biochem. Biophys. Res. Commun. (2004) 319(1):12–20.
   PubMed Web of Science ®Google Scholar
• GREEN I, CHRISTISON R, VOYCE CJ, BUNDELL KR, LINDSAY MA: Protein transduction domains: are they delivering? Trends Pharmacol Sci. (2003) 24(5):213–215.
   Google Scholar
• LUNDBERG M, WIKSTROM S, JOHANSSON M: Cell surface adherence and endocytosis of protein transduction domains. Mo/. Ther. (2003) 8(1):143–150.
   PubMed Web of Science ®Google Scholar
• RICHARD JP, MELIKOV K, VIVES E et al.: Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. (2003) 278(1):585–590.
   Google Scholar
• VIVES E, BRODIN P, LEBLEU B: A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. (1997) 272(25):16010–16017.
   PubMed Web of Science ®Google Scholar
• MEIER O, BOUCKE K, HAMMER SV et al.: Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J. Cell Biol. (2002) 158(6):1119–1131.
   PubMed Web of Science ®Google Scholar
• FITTIPALDI A, FERRARI A, ZOPPE M et al.: Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. (2003) 278(36):34141–34149.
   PubMed Web of Science ®Google Scholar
• WADIA JS, STAN RV DOWDY SF: Transducible TAT-HA fitsogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. (2004) 10(3):310–315.
   PubMed Web of Science ®Google Scholar
• ••Mechanistic insights into TAT-mediatedprotein uptake.
   Google Scholar
• FISCHER R, KOHLER K, FOTIN-MLECZEK M, BROCK R: A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biol. Chem. (2004) 279(13):12625–12635.
   PubMed Web of Science ®Google Scholar
• ZARO JL, SHEN WC: Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem. Biophys. Res. Commun. (2003) 307(2):241–247.
   PubMed Web of Science ®Google Scholar
• COLAS P, BRENT R: The impact of two-hybrid and related methods on biotechnology. Trends Biotech. (1998) 16(8):355–363.
   PubMed Web of Science ®Google Scholar
• RIESE DJ 2"d, STERN DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays (1998) 20(1):41–48.
   PubMed Web of Science ®Google Scholar
• HYNES NE: Tyrosine kinase signalling in breast cancer. Breast Cancer Res. (2000) 2(3):154–157.
   PubMed Web of Science ®Google Scholar
• BUERGER C, NAGEL-WOLFRUM K, KUNZ C et al.: Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J. Biol Chem. (2003) 278(39):37610–37621.
   PubMed Web of Science ®Google Scholar
• TURKSON J: STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets (2004) 8(5):409–422.
   PubMed Web of Science ®Google Scholar
• NAGEL-WOLFRUM K, BUERGER C, WITTIG I et al: The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. MoL Cancer Res. (2004) 2(3):170–182.
   PubMed Web of Science ®Google Scholar
• •Inhibition of transcription factor action by peptide aptamers through interference with the dimerisation and DNA-binding functions.
   Google Scholar
• XU CW, LUO Z: Inactivation of Ras function by allele-specific peptide aptamers. Oncogene (2002) 21(37):5753–5757.
   PubMed Web of Science ®Google Scholar
• XU CW, MENDELSOHN AR, BRENT R: Cells that register logical relationships among proteins. Proc. Natl Acad. Sci. USA (1997) 94(23):12473–12478.
   PubMed Web of Science ®Google Scholar
• TAPAROWSKY E, SUARD Y, FASANO O et al.: Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature (1982) 300(5894):762–765.
   PubMed Web of Science ®Google Scholar
• BEASLEY RP: Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer (1988) 61(10):1942–1956.
   Google Scholar
• BLUM JH, DOVE SL, HOCHSCHILD A, MEKALANOS JJ: Isolation of peptide aptamers that inhibit intracellular processes. Proc. Natl Acad. Sci. USA (2000) 97(5):2241–2246.
   PubMed Web of Science ®Google Scholar
• BJORKLUND M, HEIKKILA P, KOIVUNEN E: Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J. Biol Chem. (2004) 279(28):29589–29597.
   PubMed Web of Science ®Google Scholar
• KOLONIN MG, FINLEY RL JR: Targeting cyclin-dependent kinases in Drosophila with peptide aptamers. Proc. Natl Acad. Sci. USA (1998) 95(24):14266–14271.
   PubMed Web of Science ®Google Scholar
• FRANKLIN MC, KADKHODAYAN S, ACKERLY H et al.: Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry (2003) 42(27):8223–8231.
   PubMed Web of Science ®Google Scholar
• ELLIOTT S, LORENZINI T, ASHER S et al: Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. BiotechnoL (2003) 21(4):414–421.
   PubMed Web of Science ®Google Scholar
• PARK BW, ZHANG HT, WU C et al: Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. BiotechnoL (2000) 18(2):194–198.
   PubMed Web of Science ®Google Scholar
• MAI JC, MI Z, KIM SH, NG B, ROBBINS PD: A proapoptotic peptide for the treatment of solid tumors. Cancer Res. (2001) 61(21):7709–7712.
   PubMed Web of Science ®Google Scholar
• KANETO H, NAKATANI Y, MIYATSUKA T et al.: Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat. Med. (2004) 10(10):1128–1132.
   PubMed Web of Science ®Google Scholar
• ••Inhibition of the enzymatic activity ofJNKthrough a domain of the JNK-binding protein and its therapeutic effect in a type 2 diabetes model.
   Google Scholar
• CAO G, PEI W, GE H et al: In vivo delivery of a Bc1-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. j Neurosci. (2002) 22(13):5423–5431.
   PubMed Web of Science ®Google Scholar
• •Inhibition of apoptosis through a Bckc, fusion peptide.
   Google Scholar
• MATSUSHITA K, MORRELL CN, LOWENSTEIN CJ: A novel class of fusion polypeptides inhibits exocytosis. MoL Pharmacol (2005) 67(4):1137–1144.
   PubMed Web of Science ®Google Scholar
• KOLONIN MG, SAHA PK, CHAN L, PASQUALINI R, ARAP W: Reversal of obesity by targeted ablation of adipose tissue. Nat. Med. (2004) 10(6):625–632.
   PubMed Web of Science ®Google Scholar
• ZHANG X, NIEFORTH K, LANG JM et al.: Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin. Pharmacol Ther. (2002) 72(1):10–19.
   PubMed Web of Science ®Google Scholar
• KILBY JM, LALEZARI JP, ERON JJ et al.:The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retroviruses (2002) 18(10):685–693.
   PubMed Web of Science ®Google Scholar
• DIETZ GP, BAHR M: Delivery of bioactive molecules into the cell: the Trojan horse approach. MoL Cell. Neurosci. (2004) 27(2):85–131.
   PubMed Web of Science ®Google Scholar
• SEHGAL A: Recent developments in peptide-based cancer therapeutics. Curr. Opin. Drug Discov. Dev. (2002) 5(2):245–250.
   PubMed Web of Science ®Google Scholar
• KATTERLE Y, BRANDT BH, DOWDY SF et al.: Antitumour effects of PLC-gammal-(5H2)2-TAT fusion proteins on EGFRJc-erbB-2-positive breast cancer cells. Br. J. Cancer (2004) 90(1):230–235.
   PubMed Web of Science ®Google Scholar
• WASAN KM: The role of lymphatic transport in enhancing oral protein and peptide drug delivery. Drug Dev. Ind. Pharm. (2002) 28(9):1047–1058.
   PubMed Web of Science ®Google Scholar
• LANGER R: Drug delivery and targeting. Nature (1998) 392(6679 Suppl.):5–10.
   Google Scholar
• PUTNEY SD, BURKE PA: Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol (1998) 16(2):153–157.
   PubMed Web of Science ®Google Scholar
• MAHATO RI, NARANG AS, THOMA L, MILLER DD: Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. (2003) 20(2-3):153–214.
   PubMed Web of Science ®Google Scholar
• TORCHILIN VP, LEVCHENKO TS: TAT-liposomes: a novel intracellular drug carrier. Curr. Protein Pept. Sci. (2003) 4(2):133–140.
   PubMed Web of Science ®Google Scholar
• HARADA H, HIRAOKA M, KIZAKA-KONDOH S: Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res. (2002) 62(7):2013–2018.
   PubMed Web of Science ®Google Scholar
• FULDA S, WICK W, WELLER M, DEBATIN KM: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. (2002) 8(8):808–815.
   PubMed Web of Science ®Google Scholar
• SNYDER EL, MEADE BR, DOWDY SF: Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function. J. Control. Release (2003) 91(1-2):45–51.
   PubMed Web of Science ®Google Scholar
• SNYDER EL, MEADE BR, SAENZ CC, DOWDY SF: Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol. (2004) 2(2):E36.
   PubMed Web of Science ®Google Scholar
• ELLIOTT G, O'HARE P: Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell (1997) 88(2):223–233.
   PubMed Web of Science ®Google Scholar
• POOGA M, HALLBRINK M, ZORKO M, LANGEL U: Cell penetration by transportan. FASEB. J. (1998) 12(1):67–77.
   PubMed Web of Science ®Google Scholar
• OEHLKE J, SCHELLER A, WIESNER B et al.: Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta (1998) 1414(1-2):127–139.
   PubMed Web of Science ®Google Scholar
• SOOMETS U, LINDGREN M, GALLET X et al.: Deletion analogues of transportan. Biochim. Biophys. Acta (2000) 1467(1):165–176.
   PubMed Web of Science ®Google Scholar
• MI Z, MM J, LUX, ROBBINS PD: Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. MoL Ther. (2000) 2(4):339–347.
   PubMed Web of Science ®Google Scholar
• ELMQUIST A, LINDGREN M, BARTFAI T, LANGEL U: VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp. Cell Res. (2001) 269(2):237–244.
   PubMed Web of Science ®Google Scholar
• FABBRIZIO E, LE CAM L, POLANOWSKA J et al.: Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. Oncogene (1999) 18(30):4357–4363.
   PubMed Web of Science ®Google Scholar
• BUTZ K, DENK C, ULLMANN A, SCHEFFNER M, HOPPE-SEYLER F: Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci. USA (2000) 97(12):6693–6697.
   PubMed Web of Science ®Google Scholar
• •Viral oncoprotein inhibition by peptide aptamers.
   Google Scholar
• CHATTERJEE S, BRITE KH, MATSUMURA A: Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides. Clin. Cancer Res. (2001) 7(10) :3006–3011.
   PubMed Web of Science ®Google Scholar
• NAUENBURG S, ZWERSCHKE W, JANSEN-DURR P: Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein. FASEB J. (2001) 15(3):592–594.
   PubMed Web of Science ®Google Scholar
• KARDINAL C, KONKOL B, LIN H et al.: Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood (2001) 98(6):1773–1781.
   PubMed Web of Science ®Google Scholar
• KANOVSKY M, RAFFO A, DREW L et al.: Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc. Natl Acad. Sci. USA (2001) 98(22):12438–12443.
   PubMed Web of Science ®Google Scholar
• •Optimisation of a peptide sequence capable of disrupting the interaction between p53 and Mdm2.
   Google Scholar
• SCHMIDT S, DIRIONG S, MERY J, FABBRIZIO E, DEBANT A: Identification of the first Rho-GEF inhibitor, TRIPalpha, which targets the RhoA-specific GEF domain of Trio. FEBS Lett. (2002) 523(1-3):35–42.
   PubMed Web of Science ®Google Scholar
• TAMM I, TREPEL M, CARDO-VILA M et al.: Peptides targeting caspase inhibitors. J. Biol. Chem. (2003) 278(10:14401–14405.
   PubMedGoogle Scholar
• ROISIN A, ROBIN JP, DEREUDDRE-BOSQUET N et al.: Inhibition of HIV-1 replication by cell-penetrating peptides binding Rev. Biol. Chem. (2004) 279(10):9208–9214.
   Web of Science ®Google Scholar